457 results on '"Neff, Guy"'
Search Results
2. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
3. A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis
4. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
5. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
6. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
7. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
8. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
9. GS-006 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
10. LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)
11. OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial
12. SAT-227 Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM
13. SAT-243 Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
14. SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
15. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
16. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
17. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
18. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
19. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
20. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
21. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
22. Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus
23. Resmetirom helps regulate thyroid hormone levels within the liver in patients with non-alcoholic fatty liver disease
24. Non-invasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in F2-F3 NASH patients: secondary analysis of Ph2b HARMONY study
25. Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis
26. Resmetirom improves the lipid/lipoprotein profile in patients with non-alcoholic fatty liver disease
27. Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks
28. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
29. Efx treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study
30. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD
31. Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks
32. Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study
33. The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH
34. Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES
35. Su1351: TREATMENT WITH SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND PRIOR EXPERIENCE WITH OBETICHOLIC ACID OR FIBRATES
36. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma
37. Management of hypertension in liver transplant patients
38. S3397 Preliminary Analysis of FibroScan® Accuracy and Impact of Operator Aptitude
39. Survival of Human Immunodeficiency Virus-Infected Liver Transplant Recipients
40. Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
41. Hepatitis C After Liver Transplantation: Treatment and Impact on Patient and Graft Survival
42. Liver Transplantation in the Ethnic Minority Population: Challenges and Prospects
43. Rifaximin treatment in hepatic encephalopathy
44. Access to Liver Transplantation in the MELD Era: Role of Ethnicity and Insurance
45. Therapy related CMML: a case report and review of the literature
46. Ethnic Variations in Chronic Liver Diseases
47. Ethnic Differences in Hepatocellular Carcinoma: Implications for Liver Transplantation
48. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
49. Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin
50. FRI-472 - Resmetirom improves the lipid/lipoprotein profile in patients with non-alcoholic fatty liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.